← Human Trials & Peer-Reviewed Studies
Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease
Plain-language guide to PMID 15868595 (2005): double-blind randomized controlled trial study of Cholecystokinin (CCK) and Sincalide in 25 infants.
Key Facts
- PMID
- 15868595
- Journal
- Journal of pediatric surgery
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Tsai S et al. (5 authors)
- DOI
- 10.1016/j.jpedsurg.2004.09.036
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Cholecystokinin (CCK) and Sincalide, published as a randomized controlled trial.
Gallstone formation is a common problem in neonates on prolonged courses of total parenteral nutrition (TPN).
Who Took Part
The study group was 25 infants.
The age groups tagged for this paper are infants.
Children were recalled between 2 and 4 years after completing TPN for ultrasonographic examination of their hepatobiliary tree.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The infants were allocated by chance, so the Cholecystokinin (CCK) group and the comparison group should start out alike.
Blinding on both sides kept the infants and researchers unaware of who received Cholecystokinin (CCK).
A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.
A prospective, randomized, blinded, controlled trial of neonates who were on a prolonged course of TPN for prematurity (25 infants), necrotizing enterocolitis (NEC, 8 infants), or abdominal surgery (5 infants) were selected randomly to receive CCK vs placebo.
What Was Measured
Topics PubMed links to this paper include Cholagogues and Choleretics, Gallstones, Gastrointestinal Agents, Parenteral Nutrition, Total, Sincalide, Treatment Failure and Ursodeoxycholic Acid.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) and Sincalide in 25 infants.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 13 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (Journal of pediatric surgery), a journal based in United States.
More context: the Cholecystokinin (CCK) compound page and the Sincalide compound page, all human trials.
Our Notes on the Compounds
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Sincalide: A synthetic 8-amino-acid fragment of cholecystokinin (Kinevac) used in gallbladder and pancreas imaging.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.